Developing a first-in-class cholesterol-degrading therapeutic that clears excess cholesterol and reduces atherosclerotic plaque to directly address the root causes of cardiovascular disease, including heart attack and stroke.

Using plant synthetic biology to unlock the full therapeutic potential of human milk oligosaccharides for chronic and age-related disease.

Developing therapies targeting toxic crosslinks and metabolic byproducts driving aging to restore tissue function and resilience across age-related diseases.

Developing a platform that programmatically accelerates cell differentiation from months to days, enabling low-cost, high-quality cells for organoids, drug testing, and cell therapies.

Develops therapies for neurodegeneration and age-related cognitive decline by leveraging protective genetic variants rooted in human resilience.

Pioneering synthetic embryo development using patient-specific stem-cell derived embryoid models to create tissues and organs for transplantation, addressing infertility, blood disorders, liver diseases, and age-related degenerative conditions.

Addresses donor scarcity and manufacturing bottlenecks in cell therapy with advanced screening, scalable expansion, and AI-driven matching, ensuring consistent, affordable, and accessible immune cell therapies.

Utilizing the proprietary OmniTAC platform to develop next-generation induced-proximity medicines, targeting traditionally 'undruggable' proteins linked to aging and age-related diseases.

Developing highly potent small-molecule senolytic therapeutics that activate the body’s immune surveillance to selectively clear senescent cells, advancing breakthrough treatments for aging and age-related diseases.

Pioneering advanced IVF embryo screening to significantly reduce the risk of chronic age-related diseases, such as cancer and heart disease, with the potential to extend the healthy lifespan of IVF-conceived babies.

Leverages the innovative non-viral Fusogenix™ Proteo-Lipid Vehicle (PLV) platform for targeted extrahepatic delivery of genetic medicines, addressing age-related diseases like sarcopenia and obesity with enhanced precision, safety, and efficacy.

Advancing USP30 inhibitors to trigger mitophagy and enhanced mitochondrial health with a robust science driven approach. These small molecules have the potential to address aging and neurodegeneration.

Accelerating protein engineering with an automated laboratory platform that reduces cost and time for designers. Working with industry leaders Adaptyv is set to lead the growing protein design market.